



## **EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD**

### **MINUTES OF THE TEAMS MEETING 16<sup>TH</sup> SEPTEMBER 2020**

#### **PRESENT:**

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chairperson)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT (part of meeting)
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Dr R Ahmed (RA)	GP BwD CCG
Dr N Amir (NA)	Consultant Microbiologist, ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

#### **IN ATTENDANCE:**

Ms L Prince	Medicines Management Technician, EL CCG
-------------	-----------------------------------------

#### **2020/083: APOLOGIES:**

Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
------------------	---------------------------------------------------

#### **2020/084: DECLARATION OF INTEREST**

None declared – relevant to agenda items.

#### **2020/085: MINUTES OF AUGUST Teams MEETING:**

Accepted as a correct record.

#### **2020/086: MATTERS ARISING:**

**2019/131: Treatment of Vitamin B12 Deficiency Draft** – A pathway is currently being developed with Jane Oakey from Path Lab who is exploring options re. active B12 testing in the lab. LR to obtain update on progress. To be brought to ELMMB when completed.

**2020/015: New Product Request – Relvar Ellipta® & Anoro Ellipta®** - JV arranging meeting to consider their place on primary care guidelines

**2020/020: Formulary Updates - Ranolazine & Ivabradine** – Dr Singh to assist with producing a Hot Topic to support GP prescribing. JV to follow up – liaise with cardiology pharmacist.

**2020/077: Formulary Updates**

- **Sumatriptan 3mg pre-filled pen** – add to formulary to allow dose flexibility.  
**Traffic light: GREEN**
- **Sodium chloride 0.9% for nebulisation** – add to formulary as Respi-Clear and Salineb brands  
**Traffic Light: GREEN**
- **CUES eye products** – LR has fed back and is meeting with them today to discuss formulary and invite a representative to next meeting to present.
- **GlucRx safety needles** – to be taken to ELHT Medicines Safety Group. No further issues reported and training been offered to clinical teams.

**2020/087: LSCMMG CONSULTATIONS (FOR OCTOBER LSCMMG)**

**Recurrent UTI Prophylactic Antibiotic pathway** – comments from ELMMB include:

- only lower UTI is included in this pathway (NICE also includes upper UTI)
- antibiotic prophylaxis, NICE advises single dose trial first then daily prophylaxis for non-pregnant women
- refer to specialist should be for all recurrent UTI not just those with red flag symptoms
- first episode of UTI could be treated without cultures but recurrent episode should have cultures taken.

**Domperidone as galactagogue New Medicines Assessment** – agree with recommendation in line with LSCFT guidance already in use.

**Ketamine injection for chronic pain New Medicines Assessment** – concern was raised over the lack of clinical evidence for use in chronic pain. In addition it is unlicensed and there is no NICE guidance to support use. There were also significant concerns over the risks associated with abuse and addiction potential. Some patients locally are receiving this therapy at private hospitals. ELMMB recommend Black traffic light.

**Resolved: Comments to be sent to LSCMMG.**

**2020/088: LSCMMG Recommendations**

None added to website in August

**2020/089: JOINT COMMITTEE OF CCGs COMMISSIONING DECISIONS**

No meeting.

**2020/090: FORMULARY UPDATES**

**Hydrogen peroxide 1% cream** – add to formulary as included in impetigo guidance on Microguide approved last month.  
**Traffic Light: GREEN**

**Tobramycin IV for paediatrics** – add to formulary as included in antimicrobial guide for cystic fibrosis.  
**Traffic Light: RED**

**Varenicline** – Request received from respiratory consultant to prescribe, however NICE advises that prescribing should be linked to specialist behavioural management support. The website wording to be amended to reflect this and to have further discussion outside of ELMMB to try to establish co-ordinated services between primary and secondary care.

**Semaglutide oral (Rybelsus®)** – to be reviewed by LSCMMG. **Traffic Light: GREY**

**Levetiracetam in palliative care** – four community pharmacies are stocking levetiracetam injection for specialist use in palliative care for patients in the community. Change to Amber traffic light. **Traffic Light: AMBER**

**Resolved: Formulary to be updated as above**

## **2020/091: GABAPENTINOIDS**

Patient information leaflet for gabapentinoids, from Tyneside, to be added as a resource to the website. Risk of dependence to be included in the side effects before uploading. Red Whale leaflet was supported as a useful resource.

**Resolved: Add as resources for gabapentinoids to website.**

## **2020/092: DRUG SAFETY UPDATE - DENOSUMAB**

A recent Drug Safety Update (DSU) highlights the increased risk of vertebral fractures when denosumab therapy is stopped. Representatives from rheumatology, MSK service and medicine for older people to be invited to next meeting to discuss implications for existing and new patients.

**Action: Invite representatives from rheumatology, MSK and medicine for older people to next meeting.**

## **2020/093: NICE RECOMMENDATIONS (from August)**

Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant [TA640] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

**Traffic Light: RED**

Entrectinib for treating NTRK fusion-positive solid tumours (TA644) is recommended as an option by NICE. Approved in line with NICE.

Cancer Drugs Fund

**Traffic Light: RED**

## **2020/094: EAMS:**

Nivolumab treatment as a single agent of adult patients with advanced oesophageal cancer, which is inoperable or has recurred or spread following cancer chemotherapies.

Avelumab is used to treat adult patients with urothelial carcinoma (a type of bladder cancer) when it is advanced (has spread beyond the bladder) if the cancer did not get worse after an initial course of chemotherapy (including a platinum drug)

**Resolved: EAMS Nivolumab and Avelumab acknowledged**

## **STANDING ITEMS**

### **2020/095: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES – August 2020**

Minutes acknowledged

### **2020/096: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA NHS FT D&T MINUTES – July 2020**

Minutes acknowledged

Priadel discontinuation – information/ advice will soon be available from LSCFT.

**DATE OF NEXT MEETING – Wednesday 21<sup>st</sup> October 2020 12.30pm via ‘Microsoft Teams’**

**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 16<sup>th</sup> SEPTEMBER 2020**

<b>MINUTE NUMBER</b>	<b>DECSRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2019/131</b>	<b>Treatment Of Vitamin B12 Deficiency Draft</b> – pathway to be developed. Check on progress	LR/JV LR	Feb 20 Sept 20
<b>2020/015</b>	<b>New Product request – Relvar Ellipta® &amp; Anoro Ellipta®</b> - meeting to be arranged to consider place on primary care guidelines	JV	Sept 20
<b>2020/020</b>	<b>Formulary Updates – Ranolazine &amp; Ivabradine</b> – Hot Topic to support GP prescribing to be produced with assistance from Dr Singh Follow up with Dr Singh	JV  JV	Apr 20  Aug 20
<b>2020/077</b>	<ul style="list-style-type: none"> <li>- <b>CUES eye products</b> LR to meet with them today to discuss formulary products and invite them to next ELMMB meeting.</li> <li>- <b>GlucorX safety needles</b> Send information and materials re training out via Medicines Safety Group</li> </ul>	LR/JV  VG	Sep 20  Sep 20
<b>2020/092</b>	<b>Drug Safety Update – Denosumab</b> Invite representatives from rheumatology, MSK & medicine for older people to next meeting	CW/AG/LR	Oct 20